National Oncology Alliance (NOA) wants more subsidies for rare cancers

PBS landscape
Oncologists say thousands of cancer patients are either missing out on medication or being forced to spend large portions of their savings on potentially life-saving treatments because of gaps in the PBS.

The National Oncology Alliance (NOA) is calling on the Pharmaceutical Benefits Advisory Committee (PBAC) to subsidise more rare cancer treatments.

Read ABC News story here

 

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

NECA at ENETS 2025: Advancing NET Care on the Global Stage

The Australian Cancer Plan

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Walk, run, or ride this March4NETs!

For its third year, March4NETs will run throughout March 2026.

Get involved and support the 31,000 Australians living with neuroendocrine cancer.